Investigational^↗Metabolic^↗

Pemvidutide^↗

Related names in cited records: ALT-801^↗

A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. ¹

This version supersedes public version 1.

Evidence summary

What the cited records say

ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Dated source history

May 18, 2026
Clinical trials
Pemvidutide IMPACT study record updated^↗
ClinicalTrials.gov lists a completed Pemvidutide study sponsored by Altimmune, Inc.^↗